The Authors' Reply: Obesity and Allometric Scaling of Pharmacokinetics

By Diepstraten Jeroen   Knibbe Catherijne A.J.  

Clinical Pharmacokinetics, Vol. 50, Iss. 11, 2011-11 ,pp. : 755-756

Adis International

Access to resources Recommend Favorite

Allometric or Lean Body Mass Scaling of Propofol Pharmacokinetics: Towards Simplifying Parameter Sets for Target-Controlled Infusions

By >  

Clinical Pharmacokinetics, Vol. 51, Iss. 3, 2012-03 ,pp. : 137-145

Adis International

Access to resources Recommend Favorite

Mixed Effect Modeling of Sumatriptan Pharmacokinetics During Drug Development. I: Interspecies Allometric Scaling

By Cosson Valérie F.   Fuseau Eliane   Efthymiopoulos Constantin   Bye Alan  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 25, Iss. 2, 1997-04 ,pp. : 149-167

Springer Publishing Company

Access to resources Recommend Favorite

The effects of obesity on drug pharmacokinetics in humans

By Morrish Glynn A   Pai Manjunath P   Green Bruce  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 6, 2011-06 ,pp. : 697-706

Informa Healthcare

Access to resources Recommend Favorite

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

By Hanley Michael J.  

Clinical Pharmacokinetics, Vol. 49, Iss. 2, 2010-02 ,pp. : 71-87

Adis International

Access to resources Recommend Favorite